New Delhi: Drug Controller General of India (DCGI) approves Phase 2 and Phase 3 clinical trials of Bharat Biotech’s Vaccine Covaxin on children between 2 and 18 years amid growing cases of Coronavirus across the country. Has given, However, a petition has been filed in this regard in the Delhi High Court.
Vaccine trial on children challenged in Delhi High Court
Phase 2 and 3 trials on 2 to 18-year-old children of Bharat Biotech’s Vaccine Covaxin have been challenged in the Delhi High Court. According to the petition filed by Sanjeev Kumar, according to the law, the permission of the person on whom the trial is being conducted is necessary, whereas children below 18 years of age are minors and their consent does not matter legally.
Court asks for answers from Centre, no vaccine ban
While hearing the petition, the Delhi High Court has asked the Central Government to reply by issuing a notice in this regard. However, the High Court has not imposed any restriction on the trial of 2–18-year-old children of Covaxin. Chief Justice DN Patel and Justice Jyoti Singh have issued notices to the Centre and Bharat Biotech to clarify their stand on the petition by 15 July.
The vaccine trial will begin in 10-12 days
NITI Aayog member Dr V.K. Paul on Tuesday said that the clinical trial of the second and third phase of Covaxin for children between 2 and 18 years will begin in the next 10-12 days. He said, ‘Covaxin’ has been approved by the Drug Controller General of India (DCGI) for the clinical trials of Phase 2 and Phase 3 for the age group of 2 to 18 years. I have been told that the trial will begin in the next 10-12 days.
Trial will be done on 525 volunteers
It is being told that Covaxin trials will be conducted at various places, including AIIMS in Delhi and Patna, and Meditrina Institute of Medical Sciences, Nagpur. India will fully test Biotech Covaccin on 525 volunteers. Please tell that Covaxin has been made by Bharat Biotech and the Indian Council of Medical Research (ICMR) based in Hyderabad. It is one of the two vaccines that are currently being administered to adults in India.